

Long-Term Treatment Outcomes of Patients Infected With HIV: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virologic Response

Clinical Infectious Diseases

61, 730-740

DOI: 10.1093/cid/civ396

Citation Report

#	ARTICLE	IF	CITATIONS
1	Achieving Sustained Virological Response in Hepatitis C Reduces the Long-Term Risk of Hepatocellular Carcinoma: An Updated Meta-Analysis Employing Relative and Absolute Outcome Measures. Clinical Drug Investigation, 2015, 35, 843-850.	2.2	18
2	Newest Treatments for Hepatitis C: How Can We Manage Sustainability?. Clinical Infectious Diseases, 2015, 61, 1891-1892.	5.8	5
3	Hepatitis C virus treatment in the real world: optimising treatment and access to therapies: TableÂ1. Gut, 2015, 64, 1824-1833.	12.1	128
4	Treatment of Hepatitis C with First Generation Protease Inhibitors. Advances in Pharmacoeconomics & Drug Safety, 2016, 05, .	0.1	0
6	Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease. Aids, 2016, 30, 1039-1047.	2.2	42
7	The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet, The, 2016, 388, 1081-1088.	13.7	1,080
8	Clearance of Hepatitis C Virus After Fixedâ€Dose Combination Ledipasvir/Sofosbuvir in an Adolescent Female With Decompensated Cirrhosis. Journal of Pediatric Gastroenterology and Nutrition, 2016, 63, 516-517.	1.8	7
9	Treatment of chronic hepatitis C in patients with cirrhosis. Current Opinion in Gastroenterology, 2016, 32, 1.	2.3	12
10	Pharmacologic Therapies in Gastrointestinal Diseases. Medical Clinics of North America, 2016, 100, 827-850.	2.5	22
11	Hepatitis C following liver transplantation. Current Opinion in Infectious Diseases, 2016, 29, 346-352.	3.1	1
12	The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC). EBioMedicine, 2016, 12, 189-195.	6.1	89
13	Management of HCV-Associated Liver Cirrhosis. Visceral Medicine, 2016, 32, 96-104.	1.3	5
14	Role of assessing liver fibrosis in management of chronic hepatitis C virus infection. Clinical Microbiology and Infection, 2016, 22, 839-845.	6.0	42
15	Fibrosis Progression in Patients With Chronic Hepatitis C Virus Infection. Journal of Infectious Diseases, 2016, 214, 1164-1170.	4.0	17
16	Extrahepatic Manifestations of Chronic Hepatitis C Infection: a Review and Update. Current Hepatology Reports, 2016, 15, 150-157.	0.9	0
17	Followâ€up of patients with chronic hepatitis C and a sustained viral response. Liver International, 2016, 36, 67-71.	3.9	24
18	Is the benefit of treating patients with cirrhosis proven?. Liver International, 2016, 36, 21-27.	3.9	10
19	Reversion of disease manifestations after HCV eradication. Journal of Hepatology, 2016, 65, S95-S108.	3.7	143

#	ARTICLE	IF	CITATIONS
20	Management of the patient with SVR. <i>Journal of Hepatology</i> , 2016, 65, S120-S129.	3.7	54
21	Going Viral: Why Eliminating the Burden of Hepatitis C Requires Enhanced Cooperation Between Specialists and Primary Care Providers. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3381-3383.	2.3	8
22	Review article: treatment as prevention “targeting people who inject drugs as a pathway towards hepatitis C eradication. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 145-156.	3.7	11
23	End-Stage Liver Disease in HIV Infection: An Avoidable Burden?. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw537.	5.8	1
24	Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence. <i>Infectious Diseases and Therapy</i> , 2016, 5, 491-508.	4.0	28
25	Effect of coinfection with hepatitis C virus on survival of individuals with HIV-1 infection. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 521-526.	3.8	24
26	Twin epidemics of new and prevalent hepatitis C infections in Canada: BC Hepatitis Testers Cohort. <i>BMC Infectious Diseases</i> , 2016, 16, 334.	2.9	38
27	From current status to optimization of HCV treatment: Recommendations from an expert panel. <i>Digestive and Liver Disease</i> , 2016, 48, 995-1005.	0.9	13
28	Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States. <i>Infectious Agents and Cancer</i> , 2016, 11, 24.	2.6	105
29	Is response to anti-HCV treatment predictive of mortality in HCV/HIV coinfecting people?. <i>Future Virology</i> , 2016, 11, 245-248.	1.8	0
30	Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 63, S3-S11.	5.8	49
31	Advances in the management of HIV/HCV coinfection. <i>Hepatology International</i> , 2016, 10, 424-435.	4.2	47
32	Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 21-36.	3.0	9
33	Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2016, 62, 683-694.	5.8	262
34	Infectious Considerations in the Pre-Transplant Evaluation of Cirrhotic Patients Awaiting Orthotopic Liver Transplantation. <i>Current Infectious Disease Reports</i> , 2016, 18, 4.	3.0	8
35	Optimum combination therapy regimens for HIV/HCV infection. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 299-309.	4.4	2
36	Buying cures versus renting health: Financing health care with consumer loans. <i>Science Translational Medicine</i> , 2016, 8, 327ps6.	12.4	31
37	Reply to “Co-Surveillance for hepatocellular carcinoma: A tale of two countries” <i>Journal of Hepatology</i> , 2016, 64, 755-756.	3.7	2

#	ARTICLE	IF	CITATIONS
38	Eradication of hepatitis C virus and nonâ€œliverâ€œrelated nonâ€œacquired immune deficiency syndromeâ€œrelated events in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology, 2017, 66, 344-356.	7.3	49
39	Scalingâ€œup HCV treatment to achieve WHO targets by 2030. Tropical Medicine and International Health, 2017, 22, 372-374.	2.3	5
40	Characterization of chronic HCV infection in Northwest Spain: Impact of the treatment strategic plan of the Spanish National Health Service on HCV cure. Journal of Medical Virology, 2017, 89, 1304-1308.	5.0	0
41	Evaluation of a Hepatitis C Patient Management Program at a University Specialty Pharmacy. Annals of Pharmacotherapy, 2017, 51, 307-314.	1.9	13
42	Liverâ€œrelated mortality and hospitalizations attributable to chronic hepatitis C virus coinfection in persons living with <scp>HIV</scp>. HIV Medicine, 2017, 18, 685-689.	2.2	12
43	Treatment of Hepatitis C in Children. Current Hepatology Reports, 2017, 16, 18-25.	0.9	1
44	Disease Reversibility in Patients With Post-Hepatitis C Cirrhosis. Transplantation, 2017, 101, 916-923.	1.0	19
45	Interferonâ€œfree regimens improve portal hypertension and histological necroinflammation in <scp>HIV</scp>/<scp>HCV</scp> patients with advanced liver disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 139-149.	3.7	83
46	Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection. Addictive Disorders and Their Treatment, 2017, 16, S1-S23.	0.5	29
47	High prevalence of willingness to use directâ€œacting antiviralâ€œbased regimens for hepatitis C virus (<scp>HCV</scp>) infection among <scp>HIV</scp>/<scp>HCV</scp> coinfecting people who use drugs. HIV Medicine, 2017, 18, 647-654.	2.2	13
48	Con: Treating hepatitis C virus With directâ€œacting antivirals: Fear not the perceived threat of hepatocellular carcinoma. Liver Transplantation, 2017, 23, 1596-1600.	2.4	4
49	Fibrosing Cholestatic Hepatitis C After Liver Transplantation: Therapeutic Options Before and After Introduction of Direct-Acting Antivirals: Our Experience and Literature Review. Transplantation Proceedings, 2017, 49, 1409-1418.	0.6	5
50	Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection. Value in Health, 2017, 20, 1110-1120.	0.3	14
51	Effect of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival Compared With Untreated Hepatitis C Virusâ€œInfected Persons: Results From ERCHIVES. Clinical Infectious Diseases, 2017, 65, 1006-1011.	5.8	32
52	Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV). Scientific Reports, 2017, 7, 14421.	3.3	6
53	Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna. Wiener Klinische Wochenschrift, 2017, 129, 517-526.	1.9	9
55	What is the impact of treatment for hepatitis C virus infection?. Lancet, The, 2017, 390, 107-109.	13.7	12
56	A population-based study of chronic hepatitis C in immigrants and non-immigrants in Quebec, Canada. BMC Infectious Diseases, 2017, 17, 140.	2.9	31

#	ARTICLE	IF	CITATIONS
57	The impact of hepatitis C virus outside the liver: Evidence from Asia. Liver International, 2017, 37, 159-172.	3.9	38
58	Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population. Journal of Hepatology, 2017, 66, 19-27.	3.7	44
59	Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 45-52.	2.8	20
60	Reinventing HCV Treatment: Past and Future Perspectives. Journal of Clinical Pharmacology, 2017, 57, 287-296.	2.0	21
62	A Brief Update on the Treatment of Hepatitis C. , 0, , .		2
63	Rapid and large-scale implementation of HCV treatment advances in France, 2007-2015. BMC Infectious Diseases, 2017, 17, 784.	2.9	7
64	Hepatitis C is now curable, but what happens with cirrhosis and portal hypertension afterwards?. Clinical and Experimental Hepatology, 2017, 4, 181-186.	1.3	21
65	Personalized Medicine for Hepatitis C Virus. , 2017, , 485-501.		1
66	Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. Hepatology, 2018, 68, 449-461.	7.3	84
67	Development and Validation of Surveillance-Based Algorithms to Estimate Hepatitis C Treatment and Cure in New York City. Journal of Public Health Management and Practice, 2018, 24, 526-532.	1.4	11
68	Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort. Digestive Diseases and Sciences, 2018, 63, 1454-1462.	2.3	5
69	The impact of treatment of hepatitis C with <sc>DAA</sc>s on the occurrence of <sc>HCC</sc>. Liver International, 2018, 38, 139-145.	3.9	109
70	Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. Clinical Infectious Diseases, 2018, 66, 1742-1750.	5.8	21
71	Hepatitis C virus-infected kidney waitlist patients: Treat now or treat later?. American Journal of Transplantation, 2018, 18, 2443-2450.	4.7	17
72	Effectiveness and security of chronic hepatitis C treatment in coinfectd patients in real-world. International Journal of Clinical Pharmacy, 2018, 40, 608-616.	2.1	1
73	Soluble CD163 and soluble CD14 plasma levels but not cellular HIV-DNA decrease during successful interferon-free anti-HCV therapy in HIV-1-HCV co-infected patients on effective combined anti-HIV treatment. Medical Microbiology and Immunology, 2018, 207, 183-194.	4.8	20
74	The efficacy of new antiviral regimens for hepatitis C infection: Evidence from a systematic review. Hepatology, 2018, 67, 1160-1162.	7.3	3
75	Non-healthcare costs of hepatitis C: a systematic review. Expert Review of Gastroenterology and Hepatology, 2018, 12, 19-30.	3.0	15

#	ARTICLE	IF	CITATIONS
76	Epidemiological trends of deep venous thrombosis in HIV-infected subjects (1997â€“2013): A nationwide population-based study in Spain. <i>European Journal of Internal Medicine</i> , 2018, 48, 69-74.	2.2	3
77	Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population. <i>Hepatology</i> , 2018, 67, 847-857.	7.3	55
78	The benefits of hepatitis C virus cure: Every rose has thorns. <i>Journal of Viral Hepatitis</i> , 2018, 25, 320-328.	2.0	11
79	Interferon-free therapy for treating hepatitis C virus in difficult-to-treat HIV-coinfected patients. <i>Aids</i> , 2018, 32, 337-346.	2.2	6
80	Trends in pulmonary embolism in patients infected with HIV during the combination antiretroviral therapy era in Spain: A nationwide population-based study. <i>Scientific Reports</i> , 2018, 8, 12137.	3.3	4
81	The Impact of Direct-acting Antiviral Therapy for Hepatitis C on Hepatocellular Carcinoma Risk. <i>Current Hepatology Reports</i> , 2018, 17, 377-384.	0.9	14
82	Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C. <i>ClinicoEconomics and Outcomes Research</i> , 2018, Volume 10, 539-550.	1.9	4
83	Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. <i>International Journal of Drug Policy</i> , 2018, 62, 94-103.	3.3	22
84	Hepatocellular carcinoma occurrence in DAA-treated hepatitis C virus patients: Correlated or incidental? A brief review. <i>World Journal of Hepatology</i> , 2018, 10, 595-602.	2.0	12
85	KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. <i>Kidney International Supplements</i> , 2018, 8, 91-165.	14.2	141
86	The Effectiveness and Cost-Effectiveness of Hepatitis C Screening for Migrants in the EU/EEA: A Systematic Review. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 2013.	2.6	27
87	Consenso Mexicano para el Tratamiento de la Hepatitis C. <i>Revista De GastroenterologÃa De MÃ©xico</i> , 2018, 83, 275-324.	0.2	9
88	The removal of DAA restrictions in Europe â€“ One step closer to eliminating HCV as a major public health threat. <i>Journal of Hepatology</i> , 2018, 69, 1188-1196.	3.7	78
89	The effect of curing hepatitis C with direct-acting antiviral treatment on endothelial function. <i>Antiviral Therapy</i> , 2018, 23, 687-694.	1.0	9
90	Impact of Direct-Acting Antivirals on the Burden of HCV Infection Among Persons Who Inject Drugs and Men Who Have Sex With Men in the Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy154.	0.9	17
91	Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients. <i>Journal of Infectious Diseases</i> , 2018, 218, 624-632.	4.0	44
92	Significant impact of new oral therapies against HCV on the waiting list for liver transplantation in Spain. <i>Journal of Hepatology</i> , 2018, 69, 966-968.	3.7	18
93	A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-Î± and ribavirin for chronic hepatitis C virus infection. <i>Virology Journal</i> , 2018, 15, 26.	3.4	6

#	ARTICLE	IF	CITATIONS
94	The Mexican consensus on the treatment of hepatitis C. Revista De Gastroenterología De México (English Edition), 2018, 83, 275-324.	0.2	0
95	Interferon- and ribavirin-free therapy with new direct acting antivirals (DAA) for chronic hepatitis C improves vascular endothelial function. International Journal of Cardiology, 2018, 271, 296-300.	1.7	23
96	Similar Sustained Virologic Response in Real-World and Clinical Trial Studies of Hepatitis C/Human Immunodeficiency Virus Coinfection. Digestive Diseases and Sciences, 2018, 63, 2829-2839.	2.3	13
97	Reversing immune dysfunction and liver damage after direct-acting antiviral treatment for hepatitis C. Canadian Liver Journal, 2018, 1, 78-105.	0.9	3
98	Expanding treatment for hepatitis C in Canada. Cmaj, 2018, 190, E667-E668.	2.0	1
99	Pegylated Interferon- α Plus Ribavirin Therapy Improves Left Ventricular Diastolic Dysfunction in Patients With Chronic Hepatitis C Attaining Sustained Virological Response. American Journal of the Medical Sciences, 2018, 355, 566-572.	1.1	1
100	Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations. Journal of Hepatology, 2019, 71, 1116-1125.	3.7	26
101	HCV screening, linkage to care, and treatment patterns at different sites across one academic medical center. PLoS ONE, 2019, 14, e0218388.	2.5	37
102	Antiviral Consideration for Transplantation Including Drug Resistance. , 2019, , 953-975.		2
103	Evidence-making hepatitis C cure: Towards a science that knows more carefully. International Journal of Drug Policy, 2019, 72, 40-46.	3.3	14
104	Liver steatosis is a major predictor of poor outcomes in chronic hepatitis C patients with sustained virological response. Journal of Viral Hepatitis, 2019, 26, 1257-1265.	2.0	32
105	Economic evaluation of direct-acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore. JGH Open, 2019, 3, 210-216.	1.6	7
106	Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis. Cells, 2019, 8, 1249.	4.1	113
107	The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of direct acting antivirals. Liver International, 2019, 39, 2261-2272.	3.9	58
108	Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA). Scientific Reports, 2019, 9, 12502.	3.3	1
109	JN4178 (AL335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA1. Hepatology, 2019, 69, 2349-2363.	7.3	6
110	Viral Hepatitis: Chronic Hepatitis C. , 2019, , .		1
111	Achievement of hepatitis C cascade of care milestones: a population-level analysis in Alberta, Canada. Canadian Journal of Public Health, 2019, 110, 714-721.	2.3	9

#	ARTICLE	IF	CITATIONS
112	Management of HCV Infection in Decompensated Cirrhosis in the Transplantation Setting. , 2019, , 167-182.		0
113	Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: Assessment of an Italian focus group. Digestive and Liver Disease, 2019, 51, 915-921.	0.9	13
114	Long-Term Impact of Direct-Acting Antiviral Agent Therapy in HCV Cirrhosis: Critical Review. Seminars in Liver Disease, 2019, 39, 341-353.	3.6	16
115	Benefits of hepatitis C cure with antivirals: why test and treat?. Future Microbiology, 2019, 14, 425-435.	2.0	3
116	Long-term outcomes in patients with chronic hepatitis C in the current era of direct-acting antiviral agents. Expert Review of Anti-Infective Therapy, 2019, 17, 311-325.	4.4	16
117	The health equity implementation framework: proposal and preliminary study of hepatitis C virus treatment. Implementation Science, 2019, 14, 26.	6.9	183
118	Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus/HCV Coinfection in a Large US Hepatitis Clinic. Open Forum Infectious Diseases, 2019, 6, ofz099.	0.9	14
119	Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet, The, 2019, 393, 1453-1464.	13.7	449
120	Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals. Clinical Infectious Diseases, 2020, 71, 2354-2362.	5.8	23
121	A 12-week rescue therapy by PrOD-based regimen for advanced fibrotic genotype-1 CHC patients who failed to pegylated interferon plus ribavirin. Journal of the Chinese Medical Association, 2019, 82, 186-190.	1.4	3
122	UEG Week 2019 Poster Presentations. United European Gastroenterology Journal, 2019, 7, 189-1030.	3.8	6
123	Daclatasvir plus sofosbuvir, with or without ribavirin, is highly effective for all kinds of genotype-2 chronic hepatitis-C infection in Taiwan. Journal of the Chinese Medical Association, 2019, 82, 693-698.	1.4	7
124	HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals. Aids, 2019, 33, 1167-1174.	2.2	15
125	Trends in cause-specific mortality in HIV“hepatitis C coinfection following hepatitis C treatment scale-up. Aids, 2019, 33, 1013-1022.	2.2	23
126	Chronic hepatitis C infection “ Noninvasive assessment of liver fibrosis in the era of direct acting antivirals. Digestive and Liver Disease, 2019, 51, 183-189.	0.9	11
127	Disparities in uptake of direct“acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting. Liver International, 2019, 39, 1400-1407.	3.9	59
128	Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C. PLoS ONE, 2019, 14, e0208858.	2.5	4
129	Prevalence of hepatitis C virus NS5A resistance-associated substitutions in chronic infection with genotype 1: A pooled analysis based on deposited sequences in GenBank. Virus Research, 2019, 259, 54-61.	2.2	5

#	ARTICLE	IF	CITATIONS
130	Novel non-invasive score to predict cirrhosis in the era of hepatitis C elimination: A population study of ex-substance users in Singapore. Hepatobiliary and Pancreatic Diseases International, 2019, 18, 143-148.	1.3	14
131	Impact of Sustained Virologic Response with Direct-Acting Antiviral Treatment on Mortality in Patients with Advanced Liver Disease. Hepatology, 2019, 69, 487-497.	7.3	171
132	Evidence-making controversies: the case of hepatitis C treatment and the promise of viral elimination. Critical Public Health, 2019, 29, 260-273.	2.4	14
133	Elevated Fatty Liver Index as a Risk Factor for All-Cause Mortality in Human Immunodeficiency Virus-Hepatitis C Virus-Coinfected Patients (ANRS CO13 HEPACVIH Cohort Study). Hepatology, 2020, 71, 1182-1197.	7.3	8
134	Limited drug-drug interaction of elbasvir/grazoprevir for chronic hepatitis C. Journal of the Formosan Medical Association, 2020, 119, 933-940.	1.7	4
135	Hepatitis C Virus Epidemiology and the Impact of Interferon-Free Hepatitis C Virus Therapy. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a036913.	6.2	19
136	Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis. Journal of Viral Hepatitis, 2020, 27, 270-280.	2.0	27
137	Data linkage to monitor hepatitis C-associated end-stage liver disease and hepatocellular carcinoma inpatient stays in England. Journal of Viral Hepatitis, 2020, 27, 20-27.	2.0	2
138	Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology, 2020, 71, 686-721.	7.3	526
139	HCV testing: Order and completion rates among baby boomers obtaining care from seven health systems in Florida, 2015-2017. Preventive Medicine, 2021, 153, 106222.	3.4	7
140	Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: A prospective study. Journal of Viral Hepatitis, 2020, 27, 671-679.	2.0	41
141	Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study. Scientific Reports, 2020, 10, 17820.	3.3	20
142	Cost-utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China. BMJ Open, 2020, 10, e035224.	1.9	9
143	Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult. Journal of Infectious Diseases, 2020, 222, S745-S757.	4.0	9
144	Viral hepatitis in patients on hemodialysis. Seminars in Dialysis, 2020, 33, 254-262.	1.3	4
145	Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation. Journal of Infectious Diseases, 2020, 222, 1334-1344.	4.0	7
146	Knowledge, Attitudes, and Behaviors Related to Hepatitis C Screening and Treatment among Health Care Providers in Washington, DC. Journal of Community Health, 2020, 45, 785-794.	3.8	6
147	The outlook for precision medicine for the treatment of chronic hepatitis C infection: challenges and opportunities. Expert Review of Precision Medicine and Drug Development, 2020, 5, 253-263.	0.7	0

#	ARTICLE	IF	CITATIONS
148	Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy—Results from the German Hepatitis C Registry. <i>Journal of Viral Hepatitis</i> , 2020, 27, 690-698.	2.0	24
149	Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study. <i>Gut</i> , 2020, 69, 2223-2231.	12.1	17
150	Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient. <i>Renal Failure</i> , 2020, 42, 377-380.	2.1	0
151	The changing scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , 2021, 41, 585-597.	3.9	69
152	Peri-complication diagnosis of hepatitis C infection: Risk factors and trends over time. <i>Liver International</i> , 2021, 41, 33-47.	3.9	6
153	Residual risk of liver disease after hepatitis C virus eradication. <i>Journal of Hepatology</i> , 2021, 74, 952-963.	3.7	22
154	Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype 2 infection after completed treatment. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 334-345.	1.9	3
155	Cost-effectiveness of hepatitis C virus screening, and subsequent monitoring or treatment among pregnant women in the Netherlands. <i>European Journal of Health Economics</i> , 2021, 22, 75-88.	2.8	4
156	Impact of liver stiffness measurement on hepatocellular carcinoma development in chronic hepatitis C patients treated with direct-acting antivirals: A systematic review and time-to-event meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 601-608.	2.8	16
157	Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis. <i>Drugs</i> , 2021, 81, 419-443.	10.9	12
158	Experience with regorafenib in the treatment of hepatocellular carcinoma. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110169.	3.2	74
159	Emerging Management of Hepatitis C in Transplant. , 2021, , 951-969.		0
160	Serum biomarkers as an alternative to vibration controlled transient elastography in liver fibrosis staging in chronic hepatitis C. <i>Acta Gastro-Enterologica Belgica</i> , 2021, 84, 43-50.	1.0	2
161	Impact of direct-acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta-analysis. <i>Journal of Viral Hepatitis</i> , 2021, 28, 739-754.	2.0	23
162	Assessment of Liver Stiffness Regression and Hepatocellular Carcinoma Risk in Chronic Hepatitis C Patients after Treatment with Direct-Acting Antiviral Drugs. <i>Medicina (Lithuania)</i> , 2021, 57, 210.	2.0	0
163	Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 477-492.	3.7	15
164	Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addiction—A Real-world Experience. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab325.	0.9	3
165	Primary Care Providers in Federally Qualified Health Centers Can Treat Hepatitis C Effectively Without Ongoing Consultative Support From Specialists. <i>Medical Care</i> , 2021, Publish Ahead of Print, 699-703.	2.4	1

#	ARTICLE	IF	CITATIONS
166	Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. World Journal of Gastroenterology, 2021, 27, 2994-3009.	3.3	103
167	DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. Journal of Hepatology, 2020, 73, 540-548.	3.7	85
168	Trends in <sc>HCV</sc> treatment uptake, efficacy and impact on liver fibrosis in the Swiss <sc>HIV</sc> Cohort Study. Liver International, 2018, 38, 424-431.	3.9	22
169	Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease. F1000Research, 2016, 5, 367.	1.6	11
170	Stroke in HIV-infected individuals with and without HCV coinfection in Spain in the combination antiretroviral therapy era. PLoS ONE, 2017, 12, e0179493.	2.5	14
171	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. PLoS ONE, 2017, 12, e0185728.	2.5	37
172	Hepatitis C Virus Clearance by Direct-acting Antiviral Results in Rapid Resolution of Hepatocytic Injury as Indicated by Both Alanine Aminotransferase and Aspartate Aminotransferase Normalization. Journal of Clinical and Translational Hepatology, 2018, 6, 1-6.	1.4	17
173	Causes of treatment failure for hepatitis C in the era of direct-acting antiviral therapy. Revista Espanola De Enfermedades Digestivas, 2015, 108, 421-30.	0.3	2
174	Soluble Markers of Immune Activation Differentially Normalize and Selectively Associate with Improvement in AST, ALT, Albumin, and Transient Elastography During IFN-Free HCV Therapy. Pathogens and Immunity, 2018, 3, 149.	3.1	35
175	Integrated Hepatitis C Care for People Who Inject Drugs (Heplink): Protocol for a Feasibility Study in Primary Care. JMIR Research Protocols, 2018, 7, e149.	1.0	9
176	Mortality rates among individuals diagnosed with hepatitis C virus (HCV); an observational cohort study, England, 2008 to 2016. Eurosurveillance, 2019, 24, .	7.0	14
177	The role of prevention strategies in achieving HCV elimination in Canada: what are the remaining challenges?. Canadian Liver Journal, 2018, 1, 4-13.	0.9	7
178	Impact of hepatitis C oral therapy in portal hypertension. World Journal of Gastroenterology, 2017, 23, 4669.	3.3	14
179	Hepatitis C virus knowledge improves hepatitis C virus screening practices among primary care physicians. World Journal of Hepatology, 2018, 10, 319-328.	2.0	18
180	Hepatitis C virus cure with direct-acting antivirals: Clinical, economic, societal and patient value for China. World Journal of Hepatology, 2019, 11, 421-441.	2.0	12
181	Hepatitis C virus cure with direct-acting antivirals: Clinical, economic, societal and patient value for China. World Journal of Hepatology, 2019, 11, 442-449.	2.0	5
182	Hepatitis C virus: A time for decisions. Who should be treated and when?. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2016, 7, 33.	1.1	18
183	Efficacy and Safety of Generic Sofosbuvir/Ledipasvir Fixed-Dose Combination in Iranian Patients with Chronic Hepatitis C Virus Infection. Hepatitis Monthly, 2017, 17, .	0.2	13

#	ARTICLE	IF	CITATIONS
184	Assessment of Hepatitis C Virus RNA in Peripheral Blood Mononuclear Cells as a Predictor of Response to Pegylated-Interferon and Ribavirin: A Cohort Study. Iranian Red Crescent Medical Journal, 2017, 19, .	0.5	2
185	A real-world intention-to-treat analysis of a decade's experience of treatment of hepatitis C with interferon-based therapies. F1000Research, 2016, 5, 2061.	1.6	1
187	Prognostic value of blood group specificity and IL-28B genotype for the assessment of liver fibrosis in patients with chronic genotype 1 hepatitis C, non-responders to the treatment with pegylated interferon α -2 and ribavirin. Klinicheskaia Meditsina, 2017, 95, 847-854.	0.1	0
188	Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results. World Journal of Virology, 2017, 6, 59-72.	2.9	7
189	Treatment of HCV Infection with Direct-Acting Antiviral Agents in Patients with HIV/HCV Co-Infection: A Systematic Review. Hepatitis Monthly, 2018, In Press, .	0.2	1
190	Direct antiviral agents for HCV infection and hepatocellular carcinoma: facts and FADs. Translational Cancer Research, 2019, 8, S223-S232.	1.0	2
192	Emerging Management of Hepatitis C in Transplant. , 2020, , 1-20.		0
193	Major Advances in Hepatitis C Treatment but Not Hepatitis B. , 2020, , 103-129.		1
194	Evaluation of Sustained Virologic Response as a Relevant Surrogate Endpoint for Long-term Outcomes of Hepatitis C Virus Infection. Clinical Infectious Diseases, 2021, 72, 780-786.	5.8	7
196	Assessment of epidemiological situation of chronic hepatitis C in Samara Region. Medical Alphabet, 2020, , 52-54.	0.2	0
197	Cost-effectiveness of new antiviral treatments for non-genotype 1 hepatitis C virus infection in China: a societal perspective. BMJ Global Health, 2020, 5, e003194.	4.7	3
198	The HCV Treatment Revolution Continues: Resistance Considerations, Pangenotypic Efficacy, and Advances in Challenging Populations. Gastroenterology and Hepatology, 2016, 12, 1-11.	0.1	5
199	Noninvasive Assessment of Fibrosis Regression in Hepatitis C Virus Sustained Virologic Responders. Gastroenterology and Hepatology, 2017, 13, 587-595.	0.1	8
200	Cost-effectiveness of Oral Protease Inhibitors Co-administration versus Pegylated Interferon- α 2b and Ribavirin Only for the Patients with Hepatitis C Genotype 1 in Kazakhstan Health Care Settings. Iranian Journal of Public Health, 2018, 47, 1845-1853.	0.5	1
201	Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study. Caspian Journal of Internal Medicine, 2020, 11, 41-46.	0.2	1
203	The Effect of Direct Acting Antivirals on Portal Hemodynamics in Patients with Post Hepatitis C Cirrhosis: Doppler Study. International Journal of Current Microbiology and Applied Sciences, 2020, 9, 3705-3714.	0.1	1
204	Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response. World Journal of Hepatology, 2022, 14, 62-79.	2.0	3
205	Evoluci3n de los pacientes con infecci3n cr3nica por hepatitis C con fibrosis avanzada o cirrosis curados con antivirales de acci3n directa. Seguimiento a largo plazo. GastroenterologÃa Y HepatologÃa, 2022, 45, 767-779.	0.5	3

#	ARTICLE	IF	CITATIONS
206	Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long-term follow-up study. Liver International, 2022, 42, 1278-1286.	3.9	3
207	Hepatic fibrosis changes in patients with chronic hepatitis C infection who respond to direct-acting antivirals. Annals of Saudi Medicine, 2022, 42, 89-95.	1.1	1
208	Development and Validation of a Model for Prediction of End-Stage Liver Disease in People With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 89, 396-404.	2.1	1
209	HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe. HIV Medicine, 2022, 23, 684-692.	2.2	4
211	Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review. Frontiers in Public Health, 2022, 10, .	2.7	1
212	Higher Mortality in People Living with HIV after Cure of Hepatitis C by Direct-Acting Antivirals Compared to Those Without Hepatitis C: Results from the ANRS CO4 FHDH Cohort. SSRN Electronic Journal, 0, , .	0.4	0
213	Evolution of patients with chronic hepatitis C infection with advanced fibrosis or cirrhosis cured with direct-acting antivirals. Long-term follow-up. Gastroenterology & Hepatology (English Edition), 2022, 45, 767-779.	0.1	1
214	KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney International, 2022, 102, S129-S205.	5.2	10
215	The role of HIV/hepatitis B virus/hepatitis C virus RNA+ triple infection in end-stage liver disease and all-cause mortality in Europe. Aids, 2023, 37, 91-103.	2.2	1
216	Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain. PLoS ONE, 2022, 17, e0278544.	2.5	0
217	Risk factors for loss to follow-up after the start of direct-acting antiviral treatment for hepatitis C virus infection. JGH Open, 2023, 7, 98-104.	1.6	0
218	Current Landscape of HCV Therapeutics. , 2023, , 142-174.		0
219	Liver diseases: Perspective from the Philippines. Annals of Hepatology, 2023, 28, 101085.	1.5	4
220	Long-Term Monitoring of Liver Fibrosis and Steatosis in Patients with Chronic Hepatitis C after Achieving a Sustained Virologic Response to Antiviral Therapy. Russian Journal of Gastroenterology Hepatology Coloproctology, 2023, 32, 31-42.	1.1	0
221	Interventions for dialysis patients with hepatitis C virus (HCV) infection. The Cochrane Library, 2023, .	2.8	1
222	Current Therapy of Chronic Viral Hepatitis B, C and D. Journal of Personalized Medicine, 2023, 13, 964.	2.5	2
224	Unmet Needs in the Post-Direct-Acting Antiviral Era: Hepatocarcinogenesis After Hepatitis C Virus Eradication. Journal of Infectious Diseases, 2023, 228, S226-S231.	4.0	0
225	Why the United States needs a multifaceted definition of health. , 2023, 1, .		0

#	ARTICLE	IF	CITATIONS
226	Real-world treatment outcome of direct-acting antivirals and patient survival rates in chronic hepatitis C virus infection in Eritrea. Scientific Reports, 2023, 13, .	3.3	0
227	Evolution of spontaneous portosystemic shunts over time and following aetiological intervention in patients with cirrhosis. JHEP Reports, 2024, 6, 100977.	4.9	0
228	WHO hepatitis C elimination targets: the global equity challenge. The Lancet Gastroenterology and Hepatology, 2024, 9, 286-288.	8.1	0
229	Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapy. BMC Infectious Diseases, 2024, 24, .	2.9	0